



Louisiana

Experimental-Investigational Services

Policy # 00770

Original Effective Date: 03/01/2022

Current Effective Date: 03/01/2022

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Services Are Considered Investigational

Coverage is not available for investigational medical treatments, procedures, drugs, devices, or biological products.

Based on review of available data, the Company considers charges for the services listed in this policy to be **investigational/experimental**.^{*} Investigational is defined as a medical treatment, procedure, drug, device, or biological product where effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination BCBSLA makes that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the United States Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished, **OR**
- whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other non-affiliated technology evaluation center(s)
 - credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; **OR**
 - reference to federal regulations.

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Experimental-Investigational Services

Policy # 00770

Original Effective Date: 03/01/2022

Current Effective Date: 03/01/2022

Policy Guidelines

Determinations are made by the Plan after BCBSLA's review of available scientific data. Evidence based physician specialty societal guidelines, opinions of experts in a particular field and opinions and assessments of nationally recognized review organizations may also be considered by the Plan but are not determinative or conclusive.

Medical and Scientific Evidence is defined by BCBSLA as one of the following:

- Peer-reviewed scientific studies published in or accepted for publication by medical journals that meet nationally recognized requirements for scientific manuscripts and that submit most of their published articles for review by experts who are not part of the editorial staff.
- Peer-reviewed literature or biomedical compendia from such sources as the National Institute of Health's National Library of Medicine or The Cochrane Library.
- An accepted indication for treatment in one of the following standard reference compendia:
 - The American Hospital Formulary Service-Drug Information,
 - The American Medical Association Drug Evaluations,
 - The American Dental Association Accepted Dental Therapeutics, and
 - The United States Pharmacopoeia Drug Information.
- An accepted indication for treatment of cancer in one of the following standard reference compendia, for drugs approved by the FDA for treatment of cancer:
 - The National Comprehensive Cancer Network Drugs & Biologics Compendium
 - The Thomson Micromedex[®] DRUGDEX[®]
 - The Elsevier Gold Standard's Clinical Pharmacology
 - Any other authoritative compendia as recognized periodically by the United States Secretary of Health and Human Services.
- Findings, studies, or research conducted by or under the auspices of federal government agencies and nationally recognized federal research institutes including the:
 - U.S. Department of Health and Human Services,
 - Federal Agency for Healthcare Research and Quality,
 - National Institutes of Health,
 - National Cancer Institute,
 - National Academy of Sciences,
 - Center for Medicare and Medicaid Services, and

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Experimental-Investigational Services

Policy # 00770

Original Effective Date: 03/01/2022

Current Effective Date: 03/01/2022

- Any national board recognized by the National Institutes of Health for the purpose of evaluating the medical value of health services.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Policy History

Original Effective Date: 03/01/2022

12/02/2021 Medical Policy Committee review

12/08/2021 Medical Policy Implementation Committee approval. New policy.

12/20/2021 Coding Update

03/17/2022 Coding Update

03/24/2022 Coding Update

03/28//2022 Coding Update

04/06/2022 Coding Update

04/13/2022 Coding Update

05/26/2022 Coding Update

06/20/2022 Coding Update

Next Scheduled Review Date: 12/2022

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2020 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Experimental-Investigational Services

Policy # 00770

Original Effective Date: 03/01/2022

Current Effective Date: 03/01/2022

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	37790, 70371, 70557, 70558, 70559, 91132, 91133, 92520, 92572, 93998, 95060, 95065, 96904, 99605, 99606, 99607, 0017M Delete code effective 04/01/2022: 0014M, 0009U, 0294U, 0296U Delete codes effective 05/01/2022: 37187, 37188, 80280, 82656, 84145, 86001, 87801, 87809, 96146 Add codes effective 04/01/2022: 0091U, 0095U, 0317U Add codes effective 05/01/2022: 0268U, 0269U, 0270U, 0271U, 0272U, 0273U, 0274U, 0276U, 0277U, 0282U Add code effective 07/01/2022: 0331U Delete code effective 07/01/2022: 57465, 80187, 80235, 80285, 82107, 82610, 82777, 83631, 83876, 83951, 84449, 86486, 92145, 92576, 0007U, 0010U
HCPCS	A4600, A9507, C1052, C1833, C1839, C2623, C8937, C9757, C9758, C9760, C9772, C9773, C9774, C9775, E0221, G2170, G2171, K1002, K1004, S8930, S9056

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Experimental-Investigational Services

Policy # 00770

Original Effective Date: 03/01/2022

Current Effective Date: 03/01/2022

	<p>Add code effective 04/01/2022: C1824, C9781, K1030</p> <p>Delete codes effective 07/01/2022: A4563, A4639, A7047, A9589, A9597, A9598, B4105, J0591, J3570, Q3014, S8092</p>
T-Codes	<p>0054T, 0055T, 0100T, 0174T, 0175T, 0184T, 0202T, 0207T, 0208T, 0209T, 0210T, 0211T, 0212T, 0213T, 0214T, 0215T, 0216T, 0217T, 0218T, 0219T, 0220T, 0221T, 0222T, 0234T, 0235T, 0236T, 0237T, 0238T, 0278T, 0308T, 0330T, 0331T, 0332T, 0333T, 0347T, 0348T, 0349T, 0350T, 0351T, 0352T, 0353T, 0354T, 0358T, 0378T, 0379T, 0408T, 0409T, 0410T, 0411T, 0412T, 0413T, 0414T, 0415T, 0416T, 0417T, 0418T, 0419T, 0420T, 0422T, 0424T, 0425T, 0426T, 0427T, 0428T, 0429T, 0430T, 0431T, 0432T, 0433T, 0434T, 0435T, 0436T, 0437T, 0439T, 0440T, 0443T, 0444T, 0445T, 0464T, 0465T, 0469T, 0470T, 0471T, 0472T, 0473T, 0481T, 0483T, 0484T, 0485T, 0486T, 0487T, 0488T, 0491T, 0492T, 0493T, 0494T, 0495T, 0496T, 0505T, 0506T, 0507T, 0508T, 0552T, 0554T, 0555T, 0556T, 0557T, 0558T, 0563T, 0567T, 0568T, 0569T, 0570T, 0571T, 0572T, 0573T, 0574T, 0575T, 0576T, 0577T, 0578T, 0579T, 0580T, 0583T, 0591T, 0592T, 0593T, 0594T, 0596T, 0597T, 0598T, 0599T, 0600T, 0601T, 0602T, 0603T, 0609T, 0610T, 0611T, 0612T, 0613T, 0615T, 0616T, 0617T, 0618T, 0619T, 0620T, 0621T, 0622T, 0623T, 0624T, 0625T, 0626T, 0629T, 0630T, 0631T, 0632T, 0633T, 0634T, 0635T, 0636T, 0637T, 0638T, 0639T, 0640T, 0641T, 0642T, 0643T, 0644T, 0645T, 0646T, 0647T, 0652T, 0653T, 0654T, 0658T, 0659T, 0660T, 0661T, 0664T, 0665T, 0666T, 0667T, 0668T, 0669T, 0670T, 0671T, 0672T, 0673T, 0674T, 0675T, 0676T, 0677T, 0678T, 0679T, 0680T, 0681T, 0682T, 0683T, 0684T, 0685T, 0686T, 0687T, 0688T, 0689T, 0690T, 0691T, 0694T, 0695T, 0696T, 0697T, 0698T, 0700T, 0701T, 0702T, 0703T, 0704T, 0705T, 0706T, 0707T, 0710T, 0711T, 0712T, 0713T</p> <p>Delete codes effective 05/01/2022: 0290T, 0356T, 0362T, 0373T, 0423T, 0451T, 0452T, 0453T, 0454T, 0455T, 0456T, 0457T, 0458T, 0459T, 0460T, 0461T, 0462T, 0463T, 0500T</p> <p>Delete codes effective 07/01/2022: 0479T, 0480T</p> <p>Add codes effective 07/01/2022: 0607T, 0608T, 0714T, 0715T, 0716T, 0717T, 0718T, 0719T, 0721T, 0722T, 0723T, 0724T, 0725T, 0726T, 0727T, 0728T, 0729T, 0730T, 0731T, 0732T, 0733T, 0734T, 0736T, 0737T</p>

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Experimental-Investigational Services

Policy # 00770

Original Effective Date: 03/01/2022

Current Effective Date: 03/01/2022

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.